MetaCap

Akebia Therapeutics (AKBA) vs Spruce Biosciences (SPRB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Spruce Biosciences (SPRB) has outperformed Akebia Therapeutics (AKBA) over the past year, losing 63.8% versus a loss of 75.1%. Over five years, AKBA leads with a -85.6% price change compared with -99.8% for SPRB. Spruce Biosciences is the larger company by market cap ($109.2 million vs $107.0 million), about 1.0 times the size, while Akebia Therapeutics is growing revenue faster (+47.5% vs -100.0%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AKBA-75.13%SPRB-63.81%
+14%-33%-79%
Nov 21, 20251 yearNov 20, 2026
AKBA-86.13%SPRB-99.77%
+97%-6%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AKBA versus SPRB key metrics
MetricAKBASPRB
Share price$0.3855$38.00
Market cap$107.04M$109.21M
1-day change-8.71%-6.15%
YTD return-76.06%-56.38%
1-year return-75.13%-63.81%
5-year return-85.56%-99.75%
Forward P/E—11.79
EPS (TTM)$-0.17$-33.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$236.20M$0
Revenue growth (YoY)+47.46%-100.00%
Net income (latest FY)$-5.34M$-38.97M
Gross margin83.29%—
Operating margin9.95%—
Net margin-2.26%—
52-week high$1.73$111.00
52-week low$0.361$38.00
Distance from 52-week high-77.72%-65.77%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+678.21%+288.00%
Average volume8.05M89.33K
Shares outstanding277.66M2.87M
Employees19425
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SPRB has outperformed AKBA by 11.3 percentage points over the past year.
  • Akebia Therapeutics grew revenue faster in its latest fiscal year (+47.46% vs -100.00%).

About Akebia Therapeutics

AKBA stock →

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.

Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees

About Spruce Biosciences

SPRB stock →

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

AKBA vs SPRB FAQ

Which is bigger, Akebia Therapeutics or Spruce Biosciences?

Spruce Biosciences (SPRB) is larger, with a market capitalization of $109.21M compared with $107.04M for Akebia Therapeutics (AKBA).

Which stock has performed better over the past year, AKBA or SPRB?

SPRB returned -63.81% over the past 12 months, compared with -75.13% for AKBA (price return, excluding dividends). Past performance does not predict future results.

Are Akebia Therapeutics and Spruce Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons